The Academy of Managed Care Pharmacy's 24th Annual Meeting and Showcase: Specialty pharmaceutical pipeline rich with multiple sclerosis, rheumatoid arthritis, hepatitis C, cancer agentsJuly 1st 2012
Forecasts from AMCP's annual meeting indicate a full pipeline for specialty medications.
Recent FDA action (through June 2012) related to, Darunavir, Prezista, Janssen Therapeutics, Ridaforolimus, Merck, Tafamidis meglumine, Pfizer, mechlorethamine, Ceptaris Therapeutics, AVP-923, Avanir Pharmaceuticals, NKTR-181, Nektar Therapeutics, EDI200, Edimer Pharmaceuticals, Galeterone, TOK-001, Tokai Pharmaceuticals, Butoconazole nitrate 2% vaginal cream, Gynazole-1, Perrigo
Zioptan (Tafluprost 0.0015% ophthalmic solution): An opthalmic solution to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertensionJuly 1st 2012
New molecular entity: FDA approved tafluprost 0.0015% (Zioptan, Merck) ophthalmic solution to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Extended treatment with Alzheimer's drugs may provide modest cognitive benefit, study showsJuly 1st 2012
A new study of patients with moderate-to-severe Alzheimer's disease found that extended treatment with donepezil could improve cognition and function for even severe patients; however, experts caution that the benefits of the drug were modest.
American Psychiatric Association 2012 Annual Meeting: Clinical updates review findings on long-acting levomilnacipran in major depressive disorder, depot versus oral antipsychotics for schizophreniaJuly 1st 2012
A review of drug therapies and research presented at the 2012 Annual Meeting of the American Psychiatric Association
Payers seek more comparative research documenting value and affordability of high-cost therapiesJuly 1st 2012
While scientists and biomedical researchers at the recent meeting of the American Society of Clinical Oncology (ASCO) applauded encouraging data on dozens of breakthrough cancer therapies, analysts pondered strategies for convincing payers to cover the new life-saving drugs.
Rising costs due to behavior-driven conditions significantly impact health plan costs, report saysJuly 1st 2012
The rising cost of specialty drugs, challenges with medication adherence, and the utilizations of mail order are among the top trends impacting employers and other health plan sponsors, according to a recent report about prescription benefit management trends.
Gain a solid understanding of compendia and its impact on patient accessJuly 1st 2012
The current compendia landscape, through constantly in flux, impacts everything from payer approval of off-label use to manufacturer patient access initiatives. Drug compendia, defined as summaries of drug information, affects coverage and reimbursement decisions for pharmaceuticals products, and as a result, it's important for pharmaceitucal manufacturers and healthcare providers to understand the role and impact of compendia off-label uses.
Surfaxin (Lucinactant): An intratracheal suspension indicated for the prevention of respiratory distress syndrome in premature infantsJune 1st 2012
New molecular entity: FDA approved lucinactant (Surfaxin, Discovery Laboratories) for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk of RDS.
Recent FDA action (through May 2012) related to, Loxapine, Adasuve, Alexza Pharmaceuticals, Denosumab, Xgeva, Amgen, Furiex, Takeda, Nesina, alogliptin, fixed-dose combination alogliptin and pioglitazone, Liovel, Emtricitabine and tenofovir disoproxil fumarate, Truvada, Gilead Sciences, Lorcaserin, Arena Pharmaceuticals, Eisai, Tofacitinib, Pfizer, Tafamidis, ACH-3102, Achillion, CK-2017357, Cytokinetics, Taliglucerase alfa, Elelyso, Pfizer, Carisbamate, SK Biopharmaceuticals, Vancomycin hydrochloride, Vancocin, Akorn, Watson
Expansion paradigm of nonprescription drugs could improve efficiencies and access, but raises quality issuesJune 1st 2012
As FDA considers a new paradigm that would expand the definition of nonprescription drugs, healthcare experts say the proposed paradigm could have its benefits and challenges for the healthcare industry.
Omontys (Peginesatide): The first pegylated erythropoiesis-stimulating agent for the treatment of anemia due to CKD in adults undergoing dialysisJune 1st 2012
New molecular entity: FDA approved the synthetic, pegylated erythropoiesis-stimulating agent (ESA) peginesatide (Omontys, Affymax) for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis.
Atypical antipsychotics may help refractory depressionMay 25th 2012
The use of atypical antipsychotics in patients with major depressive disorder who have not responded to antidepressant therapy substantially increased clinical response rates at 6 weeks; however the drugs are also much more costly, according to the results of an analysis published in the May issue of The Annals of Pharmacotherapy.
FDA completes safety review of MS drugMay 25th 2012
The multiple sclerosis drug fingolimod (Gilenya, Novartis) is now contraindicated for use in patients with certain pre-existing or recent heart conditions or stroke, or who are taking certain antiarrhythmic medications, according to FDA
Improvements in warfarin therapy reduce stroke rate, study showsMay 11th 2012
Current use of warfarin as a stroke prevention therapy in patients with nonvalvular atrial fibrillation is associated with a lower rate of residual stroke or systemic embolism compared with previous data, according to a recent study published in the Archives of Internal Medicine.